Mechanical circulatory support versus vasopressors alone in patients with acute myocardial infarction and cardiogenic shock undergoing percutaneous coronary intervention

Abstract

AbstractBackgroundPrevious studies have compared Impella use to intra‐aortic balloon pump (IABP) use in patients with acute myocardial infarction and cardiogenic shock (AMI‐CS) undergoing percutaneous coronary intervention (PCI). Our objective was to compare clinical outcomes in patients with AMI‐CS undergoing PCI who received Impella (percutaneous left ventricular assist device) without vasopressors, IABP without vasopressors, and vasopressors without mechanical circulatory support (MCS).MethodsWe queried the National Inpatient Sample (NIS) using ICD‐10 codes (2015–2018) to identify patients with AMI‐CS undergoing PCI. We created three propensity‐matched cohorts to examine clinical outcomes in patients receiving Impella versus IABP, Impella versus vasopressors without MCS, and IABP versus vasopressors without MCS.ResultsAmong 17,762 patients, Impella use was associated with significantly higher in‐hospital major bleeding (31.4% vs. 13.6%; p < 0.001) and hospital charges (p < 0.001) compared to IABP use, with no benefit in mortality (34.1% vs. 26.9%; p = 0.06). Impella use was associated with significantly higher mortality (42.3% vs. 35.7%; p = 0.02), major bleeding (33.9% vs. 22.7%; p = 0.001), and hospital charges (p < 0.001), when compared to the use of vasopressors without MCS. There were no significant differences in clinical outcomes between IABP use and the use of vasopressor without MCS.ConclusionsIn this analysis of retrospective data of patients with AMI‐CS undergoing PCI, Impella use was associated with higher mortality, major bleeding, and in‐hospital charges when compared to vasopressor therapy without MCS. When compared to IABP use, Impella was associated with no mortality benefit, along with higher major bleeding events and in‐hospital charges. A vasopressor‐only strategy suggested no difference in clinical outcomes when compared to IABP. This study uses the NIS for the first time to highlight outcomes in AMI‐CS patients undergoing PCI when treated with vasopressor support without MCS, compared to Impella and IABP use.